2003年6月
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer
LUNG CANCER
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 40
- 号
- 3
- 開始ページ
- 339
- 終了ページ
- 342
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/S0169-5002(03)00043-6
- 出版者・発行元
- ELSEVIER SCI IRELAND LTD
ZD 1839 is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). We now present a case of diffuse alveolar damage (DAD) that developed in a 67-year-old man treated with ZD1839. On day 8 of ZD1839 administration, the patient complained of dyspnea and a new-ground glass opacity was apparent on a chest X-ray and computed tomography scan. Despite high-dose steroid therapy, the patient died 13 days after the first administration of ZD1839. Postmortem analysis of lung tissue revealed a pattern of DAD. No evidence of infection or of other specific etiologies was apparent. This case is the first reported of respiratory failure after ZD1839 treatment in a patient with NSCLC. Physicians should therefore be aware of the potential pulmonary toxicity of ZD1839. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/S0169-5002(03)00043-6
- ISSN : 0169-5002
- Web of Science ID : WOS:000183391800014